1.255

2.46% 0.035

Pacific Biosciences Of California Inc (PACB)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PACB? Forum Prognose

Schlusskurs vom Vortag:

$1.22

Offen:

$1.24

24-Stunden-Volumen:

5.47M

Relative Volume:

0.92

Marktkapitalisierung:

$389.81M

Einnahmen:

$160.03M

Nettoeinkommen (Verlust:

$-128.58M

KGV:

-2.9405

EPS:

-0.4268

Netto-Cashflow:

$-121.21M

1W Leistung:

+8.70%

1M Leistung:

-19.87%

6M Leistung:

-47.70%

1J Leistung:

+35.60%

1-Tages-Spanne:

$1.19

$1.28

1-Wochen-Bereich:

$1.14

$1.285

52-Wochen-Spanne:

$0.8511

$2.73

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Firmenname

Pacific Biosciences Of California Inc

Sektor

Healthcare (1110)

Branche

Medical Devices (143)

Telefon

650-521-8000

Adresse

1305 O'BRIEN DRIVE, MENLO PARK, CA

Mitarbeiter

485

Twitter

@pacbio

Nächster Verdiensttermin

2026-05-07

Neueste SEC-Einreichungen

PACB's Discussions on Twitter

Compare PACB vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PACB Pacific Biosciences Of California Inc	1.255	378.93M	160.03M	-128.58M	-121.21M	-0.4268
ABT Abbott Laboratories	86.67	152.25B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	312.11	121.33B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	77.83	100.91B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	57.84	85.88B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	87.75	49.39B	6.30B	1.07B	1.09B	1.8406

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-06	Herabstufung	Barclays	Equal Weight → Underweight
2024-11-11	Herabstufung	UBS	Buy → Neutral
2024-06-03	Fortgesetzt	Jefferies	Buy
2024-04-22	Herabstufung	JP Morgan	Overweight → Neutral
2024-04-18	Herabstufung	Goldman	Buy → Neutral
2023-12-14	Eingeleitet	Guggenheim	Neutral
2023-12-14	Eingeleitet	Stephens	Overweight
2023-12-13	Eingeleitet	Wolfe Research	Peer Perform
2023-11-17	Hochstufung	UBS	Neutral → Buy
2023-10-31	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2023-09-28	Eingeleitet	Bernstein	Outperform
2023-07-05	Fortgesetzt	JP Morgan	Overweight
2023-06-30	Eingeleitet	Goldman	Buy
2023-05-10	Eingeleitet	Barclays	Equal Weight
2023-03-31	Hochstufung	TD Cowen	Market Perform → Outperform
2023-02-02	Eingeleitet	UBS	Neutral
2023-01-20	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-01-05	Eingeleitet	Scotiabank	Sector Outperform
2022-01-21	Fortgesetzt	Cantor Fitzgerald	Overweight
2022-01-06	Fortgesetzt	Piper Sandler	Neutral
2021-10-15	Fortgesetzt	Cowen	Market Perform
2021-09-27	Eingeleitet	Canaccord Genuity	Buy
2021-02-11	Hochstufung	Piper Sandler	Neutral → Overweight
2020-11-03	Herabstufung	Piper Sandler	Overweight → Neutral
2020-10-02	Hochstufung	JP Morgan	Neutral → Overweight
2020-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2020-06-02	Fortgesetzt	Cantor Fitzgerald	Overweight
2020-03-09	Fortgesetzt	Cantor Fitzgerald	Overweight
2019-10-15	Hochstufung	Piper Jaffray	Neutral → Overweight
2019-04-02	Herabstufung	Stephens	Overweight → Equal-Weight
2018-10-19	Eingeleitet	Cowen	Outperform
2017-11-03	Herabstufung	First Analysis Sec	Overweight → Equal-Weight
2017-09-28	Herabstufung	CL King	Buy → Neutral
2016-11-03	Bestätigt	Cantor Fitzgerald	Buy
2016-06-27	Eingeleitet	CL King	Buy
2016-04-15	Eingeleitet	First Analysis Sec	Overweight
2016-02-04	Herabstufung	Piper Jaffray	Overweight → Neutral
2016-01-04	Bestätigt	Cantor Fitzgerald	Buy
2015-10-23	Hochstufung	Piper Jaffray	Neutral → Overweight
2015-08-27	Eingeleitet	Cantor Fitzgerald	Buy
2015-02-04	Bestätigt	Maxim Group	Buy
2013-09-26	Bestätigt	Maxim Group	Buy
2013-01-14	Bestätigt	Maxim Group	Buy

Alle ansehen

Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten

11:42 AM

Pacbio Ships Sprq-Nx Chemistry and Multi-Use Smrt Cells for Revio Hifi Sequencing Platform Worldwide - marketscreener.com

11:42 AM

10:07 AM

PACB (Pacific Biosciences of California) ROC % : -47.66% (As of Mar. 2026) - GuruFocus

May 24, 2026

May 23, 2026

Q4 2025 Pacific Biosciences of California Inc Earnings Call Transcript - GuruFocus

May 23, 2026

May 22, 2026

PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill

May 22, 2026

May 21, 2026

PacBio to Participate in the Jefferies Global Healthcare Conference - Yahoo Finance

May 21, 2026

Here's why you should add PacBio stock to your portfolio now - MSN

May 21, 2026

Pacific Biosciences of California (PACB) Stock Price, News & Analysis - MarketBeat

May 21, 2026

May 20, 2026

Pacific Biosciences of California sets $300 price point for 20x human genome sequencing on Revio - Traders Union

May 20, 2026

PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology - Yahoo Finance

May 20, 2026

May 19, 2026

PACB Secures $7.2M in Seed Funding and Partners with Blank Bio - GuruFocus

May 19, 2026

PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN

May 19, 2026

Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology - BioSpace

May 19, 2026

AI lab Blank Bio raises $7.2M, teams with PacBio on tumor RNA - Stock Titan

May 19, 2026

PacBio tumbles after narrowing full-year revenue guidance - MSN

May 19, 2026

May 18, 2026

Sequencing constraints lifted as Pacific Biosciences of California enables combined genetic and methylation detection - Traders Union

May 18, 2026

PacBio expects $165M-$175M 2026 revenue as SPRQ-Nx ships later this month - MSN

May 18, 2026

May 14, 2026

Pacific Biosciences of California introduces HiFi Starter Kit to expand long-read sequencing access - Traders Union

May 14, 2026

Pacific Biosciences stock (US6932471010): Latest developments and market position - AD HOC NEWS

May 14, 2026

PACB SEC FilingsPacific Biosc 10-K, 10-Q, 8-K Forms - Stock Titan

May 14, 2026

PACB Technical Analysis | Trend, Signals & Chart Patterns | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill

May 14, 2026

PacBio (PACB) Q1 earnings report preview: What to look for - MSN

May 14, 2026

May 13, 2026

Pacific Biosciences (PACB) Reports Q1 EPS - Insider Monkey

May 13, 2026

Pacific Biosciences of California brings global researchers together in Fukuoka - Traders Union

May 13, 2026

May 12, 2026

Why PacBio (PACB) Shares Are Getting Obliterated Today - Yahoo Finance

May 12, 2026

5 Best Penny Stocks to Buy Before They Explode - Insider Monkey

May 12, 2026

PACB Q1 Deep Dive: Consumables Growth and Clinical Adoption Offset Instrument Weakness - Yahoo Finance

May 12, 2026

May 11, 2026

Pacific Biosciences of California launches PacBioPRISM tour finale in Japan to drive HiFi innovation - Traders Union

May 11, 2026

Pacific Biosciences of California, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PACB) 2026-05-11 - Seeking Alpha

May 11, 2026

PACB Maintained by Barclays -- Price Target Raised to $1.50 - GuruFocus

May 11, 2026

TradingKey - TradingKey

May 11, 2026

Long-read genome scan spots key variants in unexplained subfertility - Stock Titan

May 11, 2026

May 09, 2026

PacBio (PACB) Q1 2026 Earnings Call Transcript - AOL.com

May 09, 2026

Pacific Biosciences Of California (PACB) Q4 Loss Highlights Ongoing Break From Bullish Profitability Narratives - Sahm

May 09, 2026

Pacific Biosciences of California, Inc. Q1 2026 Financial Results and SEC 10-Q Filing Highlights - Minichart

May 09, 2026

May 08, 2026

[10-Q] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Quarterly Earnings Report - Stock Titan

May 08, 2026

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1Q 2026: Revenue $37.18M, EPS ($0.03) — 10-Q Summary - TradingView

May 08, 2026

Pacific Biosciences stock (US6932471010): Flat Q1 revenue amid funding pressure in U.S. research sec - AD HOC NEWS

May 08, 2026

Pacific Biosciences (PACB) Shares Drop Following Q1 Revenue Miss - GuruFocus

May 08, 2026

Pacific Biosciences Shares Fall Amid 1Q Revenue Pressures - Moomoo

May 08, 2026